|
| A) | Decline to provide any dose information since this would constitute facilitating illegal drug use. | ||
| B) | Provide specific dose ranges based on research protocols since these represent evidence-based practice. | ||
| C) | Refer the client to online psychedelic forums where they can find dosing information. | ||
| D) | You cannot provide recommendations but can educate about general dose ranges, individual variability, and the importance of starting low. |
| A) | Decline to provide referrals but offer to help them develop criteria for evaluating facilitators themselves. | ||
| B) | Give them websites where they can find facilitator directories and reviews. | ||
| C) | Immediately explain you cannot provide such referrals as it could constitute facilitating illegal activity. | ||
| D) | Provide names of facilitators you have heard positive things about, with disclaimers about legality. |
| A) | Increased risk of cardiovascular complications from the interaction | ||
| B) | Potential for increased depression after the psychedelic experience ends | ||
| C) | Risk of serotonin syndrome requiring emergency intervention | ||
| D) | Significantly reduced or absent psychedelic effects due to SSRI blockade |
| A) | Explain that challenging experiences often produce the most growth and encourage them to try again. | ||
| B) | Explore what was challenging and why, what they learned from it, and what different approaches might address those factors. | ||
| C) | Recommend the client not use psychedelics again as they had a bad trip. | ||
| D) | Suggest they try a different psychedelic since they may have better experiences with other substances. |
| A) | Cardiovascular stress testing | ||
| B) | Cognitive function assessment | ||
| C) | Liver function testing | ||
| D) | Urological evaluation for bladder and kidney function |
| A) | Discuss the elevated risk, recommend psychiatric consultation, and explore the risk-benefit profile collaboratively. | ||
| B) | Inform the client that family history is an absolute contraindication and recommend against use. | ||
| C) | Reassure the client that family history without personal symptoms presents no additional concern. | ||
| D) | Suggest the client try a different psychedelic with lower risks. |
| A) | Discuss the elevated risks, the specific concern about lithium interactions, and recommend consultation with their psychiatrist. | ||
| B) | Inform them that bipolar disorder is an absolute contraindication for any psychedelic use. | ||
| C) | Reassure them that since they are stable, psychedelic use should be safe. | ||
| D) | Suggest they discontinue lithium before using psilocybin to avoid interactions. |
| A) | Document the disclosure and continue with the session agenda without addressing it further. | ||
| B) | Explore their intentions, provide harm reduction education, and discuss safety planning. | ||
| C) | Terminate the session and require the client to commit to abstinence before continuing therapy. | ||
| D) | Warn the client about legal consequences and recommend they not use illegal substances. |
| A) | Assessing whether the client's employer or family knows about this use | ||
| B) | Determining if this use pattern meets criteria for substance use disorder | ||
| C) | Educating the client about legal consequences of Schedule I substance use | ||
| D) | Exploring the client's understanding of safety, contraindications, and harm reduction |
| A) | Explain these experiences as psychological phenomena rather than actual contact with the deceased. | ||
| B) | Explore the personal meaning and impact of the experience without imposing your own interpretation. | ||
| C) | Recommend psychiatric evaluation to rule out psychotic symptoms. | ||
| D) | Validate that these experiences represent genuine spiritual contact. |
| A) | All clients should undergo cardiac stress testing before using psychedelics. | ||
| B) | Classic psychedelics cause dangerous cardiovascular effects requiring cardiac monitoring. | ||
| C) | Modest increases in heart rate and blood pressure mean those with serious cardiovascular disease should consult their physician. | ||
| D) | These substances have no cardiovascular effects and are safe for all populations. |
| A) | Agree only if the experience takes place in your office during scheduled sessions | ||
| B) | Agree only if they procure and self-administer psilocybin, as this represents harm reduction | ||
| C) | Explain this would exceed your scope of practice and professional boundaries, then help them identify appropriate support | ||
| D) | Report this request to your licensing board as it constitutes solicitation of illegal activity |
| A) | Avoiding high doses and limiting experiences to microdosing levels only | ||
| B) | Ensuring a trusted, sober support person is present who can provide reassurance and grounding | ||
| C) | Taking benzodiazepines to reduce anxiety during the experience | ||
| D) | Using psychedelics only in clinical or medical settings with professional supervision |
| A) | Clients disclosing illegal drug use during therapy sessions | ||
| B) | Continuing to treat clients after learning about their psychedelic use | ||
| C) | Directly recommending specific doses or sources for obtaining psychedelics | ||
| D) | Providing education about harm reduction strategies for psychedelic use |
| A) | Psychedelic-informed practice focuses only on integration while psychedelic-assisted therapy includes preparation. | ||
| B) | Psychedelic-informed practice is legal in all states while psychedelic-assisted therapy is federally prohibited. | ||
| C) | Psychedelic-informed practice requires specialized certification while psychedelic-assisted therapy does not. | ||
| D) | Psychedelic-informed practice supports clients who use substances independently, while psychedelic-assisted therapy involves direct administration or facilitation. |